Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 17/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740944 | 0.88 | PTPN1 (0.65) | PTPN1NR1H4 | |
| SCHEMBL6730810 | 0.88 | PTPN1 (0.61) | PTPN1EGFRSRCABL1ABL2 | |
| SCHEMBL6735734 | 0.86 | PTPN1 (0.56) | PTPN1EGFRSRCABL1ABL2 | |
| SCHEMBL6739280 | 0.84 | PTPN1 (0.59) | PTPN1NR1H4 | |
| SCHEMBL6731868 | 0.77 | PTPN1 (0.58) | PTPN1NR1H4 | |
| SCHEMBL7564914 | 0.75 | PTPN1 (0.53) | PTPN1NR1H4 | |
| SCHEMBL7592978 | 0.72 | PTPN1 (1.00) | PTPN1 | |
| SCHEMBL6741511 | 0.72 | EYA3 (0.62) | PTPN1NR1H4 | |
| SCHEMBL6934146 | 0.69 | PTPN1 (0.55) | PTPN1NR1H4 | |
| SCHEMBL6736009 | 0.68 | PTPN1 (0.63) | PTPN1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683107-B2 | THERAPY OF METABOLISM DISORDERS | WYETH | 2004-01-27 | — | — | US | disclosed |
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, FFAR3 | PTPN1 178/4885EGFR 536/4885SRC 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.